Liquid biopsy market projects 25.2% CAGR growth until 2028

Buying behaviour is influenced by patient demographics and healthcare policies.

The global liquid biopsy market is projected to rise by $3.69b until 2028 at an estimated compound annual growth rate (CAGR) of almost 25.2%.

A report by Technavio revealed that the market is witnessing notable growth due to the increasing demand for minimally invasive diagnostic solutions amidst the prevalence of cancer and the potential for customised therapies.

In line with this, awareness initiatives, breast and cervical cancer screening, and next-generation sequencing (NGS) technology advancements are further contributing to market growth.

Meanwhile, Technavio cited that the market’s buying behaviour is also influenced by patient demographics and healthcare policies.

“In developed markets, advanced technologies and NGS are driving the growth of the market, whilst in developing economies, cost-effectiveness and accessibility are key factors,” the report said.

Moreover, medical tourism is projected to impact growth, with patients from developing economies shifting towards quality and affordable services in developed markets.